SPTX Seaport Therapeutics, Inc. Insider Trading

Director Robert J. Hombach buys 13,000 shares of SPTX at $18.14 for $235.8K; first position, amid -$25.4M net loss

Robert J. Hombach, a Director, completed his first purchase of Seaport Therapeutics stock, acquiring 13,000 shares at $18.14 on 2026-06-22 for $235.8K. The purchase occurs while the company reported net income of -$25,408,000.00, indicating significant operating losses. The stock currently trades at $18.97, 8.4% above the 30-day average, but 17.5% below its 52-week high of $23.00, positioning this buy within a compressed valuation zone. This inaugural Director purchase of material size warrants monitoring to assess whether it reflects confidence in Seaport's near-term trajectory or commercialization milestones.

ARCH Venture Partners XII acquires over 5M shares in SPTX IPO aftermath; major institutional vote of confidence at listing price

ARCH Venture Partners XII, a 10% beneficial owner of Seaport Therapeutics, executed a substantial open-market purchase of over 5 million shares on the stock's second trading day—a significant institutional commitment that coincides with the company's recent IPO. The timing is notable: the fund is buying at the listing price level after having already participated in the private placement rounds that likely seeded its beneficial ownership stake. This isn't insider knowledge driving the trade, but rather portfolio capital allocation—ARCH is doubling down on its conviction in the biotech therapeutics opportunity the company represents. The purchase reflects institutional confidence that the newly public shares offer fair value at current levels, which could signal that the market's initial pricing is reasonable from the fund's perspective.